Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclosporine A versus cyclophosphamide for polymyositis/dermatomyositis-associated interstitial lung disease
ChiCTR1900025087Phase 4Not yet recruiting
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Sep 2019
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of cyclosporine and cyclophosphamide in polymyositis or dermatomyositis-associated interstitial lung disease (PM/DM-ILD) (2 arms), sponsored by Guangdong Provincial People's Hospital. Primary endpoint: Forced vital capacity percent predicted. Planned start Sep 2019; status: not yet recruiting.
02
Drugs
cyclosporinecyclophosphamide
03
Conditions
polymyositis or dermatomyositis-associated interstitial lung disease (PM/DM-ILD)
Beyond the preview
Go deeper on ChiCTR1900025087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900025087.